Journal article
Systematic review: safety of mesalazine in ulcerative colitis
Abstract
BACKGROUND: Mesalazine is the most commonly prescribed medication for mild to moderate ulcerative colitis. It is generally well tolerated with some reported side effects.
AIM: To summarise adverse drug events to mesalazine and recommend techniques for management. Furthermore, to determine if there is a dose-dependent relationship between high (>2.4 g/day) vs low dosing (≤2.4 g/day) and occurrence of adverse drug events.
Authors
Sehgal P; Colombel J; Aboubakr A; Narula N
Journal
Alimentary Pharmacology & Therapeutics, Vol. 47, No. 12, pp. 1597–1609
Publisher
Wiley
Publication Date
June 2018
DOI
10.1111/apt.14688
ISSN
0269-2813